Dendritic Cell News and Research

Latest Dendritic Cell News and Research

NewLink Genetics announces results from two clinical studies with indoximod

NewLink Genetics Corporation, an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from two clinical studies with indoximod, an orally administered small molecule drug candidate that inhibits the IDO pathway.

3 Jun 2013

DCPrime completes DCP-001 Phase I/IIa study in patients with acute myeloid leukemia

Cancer vaccine company DCPrime today announced the successful completion of its Phase I/IIa study in acute myeloid leukemia.

28 May 2013

NW Bio starts Phase III clinical trial with DCVax-L for brain cancer at King's College Hospital in UK

Northwest Biotherapeutics, a biotechnology company developing DCVax-L personalized immune therapies for solid tumor cancers, today announced that its Phase III clinical trial with DCVax-L for brain cancer has been initiated at King's College Hospital in the UK.

17 May 2013

Researchers reveal how Ebola evades human immune response

Researchers have discovered the mechanism behind one of the Ebola virus' most dangerous attributes: its ability to disarm the adaptive immune system.

3 May 2013

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Nanogels are synthetic particles that can be used for drug delivery. They are approximately 100 nm to 200 nm in diameter, and are made from safe, biocompatible materials: a gel-like interior and a lipid exterior.

24 Apr 2013

GBM brain cancer patient treated with DCVax-L celebrates 10th anniversary of cancer-free survival

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced today that Brad Silver, an All American swimming and water polo athlete who was diagnosed with Glioblastoma multiforme brain cancer in late 2002, and was treated with DCVax-L in March of 2003, just celebrated the 10th anniversary of his continued cancer-free survival.

19 Apr 2013

New immunotherapies are seldom developed for childhood cancer

More often than not, cancer immunotherapies that work in adults are used in modified ways in children. Seldom are new therapies developed just for children, primarily because of the small number of pediatric patients relative to the adult cancer patient population.

9 Apr 2013

New two-step immunotherapy approach offers new hope for ovarian cancer patients

As many as three quarters of advanced ovarian cancer patients appeared to respond to a new two-step immunotherapy approach -- including one patient who achieved complete remission -- according research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today in a press conference at the AACR Annual Meeting 2013 (Presentation #LB-335).

8 Apr 2013

Nobel Prize recipient describes on innate immunity at Annual Drosophila Research Conference

A young scientist's astute observation - that grasshoppers don't get sick - eventually led to profound insights into our own immunity.

6 Apr 2013

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.

2 Apr 2013

Kaposi’s sarcoma risk factors revealed

Scientists have uncovered an intriguing relationship between the risk for Kaposi’s sarcoma, smoking, and the use of highly active antiretroviral therapy.

25 Feb 2013

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma is a devastating disease. There are roughly 20-25,000 new cases per year in the United States and it is increasing for some reason.

12 Feb 2013

Two-step personalized immunotherapy safe for patients with ovarian cancer

Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies. In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania School of Medicine show that a two-step personalized immunotherapy treatment - a dendritic cell vaccine using patients' own tumor followed by adoptive T cell therapy - triggers anti-tumor immune responses in these type of patients.

1 Feb 2013

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

CEL-SCI Corporation announced that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease.

31 Jan 2013

FDA allows IND application for ImmunoCellular’s ICT-140 to treat ovarian cancer

ImmunoCellular Therapeutics, Ltd. announced that the US Food and Drug Administration (FDA) has allowed the investigational new drug (IND) application for ICT-140, paving the way for conducting a clinical trial.

30 Jan 2013

Antibodies essential for dendritic cell maturation

Dendritic cells, or DCs for short, perform a vital role for the immune system: They engulf pathogens, break them down into their component parts, and then display the pieces on their surface.

23 Jan 2013

Study explains how Timothy syndrome mutation causes wiring defects that underlie cognition

A new finding in neuroscience for the first time points to a developmental mechanism linking the disease-causing mutation in an autism-related disorder, Timothy syndrome, and observed defects in brain wiring, according to a study led by scientist Ricardo Dolmetsch and published online yesterday in Nature Neuroscience.

16 Jan 2013

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

NewLink Genetics announces results from two clinical studies with indoximod

DCPrime completes DCP-001 Phase I/IIa study in patients with acute myeloid leukemia

NW Bio starts Phase III clinical trial with DCVax-L for brain cancer at King's College Hospital in UK

Researchers reveal how Ebola evades human immune response

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

GBM brain cancer patient treated with DCVax-L celebrates 10th anniversary of cancer-free survival

New immunotherapies are seldom developed for childhood cancer

New two-step immunotherapy approach offers new hope for ovarian cancer patients

Nobel Prize recipient describes on innate immunity at Annual Drosophila Research Conference

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

Kaposi’s sarcoma risk factors revealed

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Two-step personalized immunotherapy safe for patients with ovarian cancer

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

FDA allows IND application for ImmunoCellular’s ICT-140 to treat ovarian cancer

Antibodies essential for dendritic cell maturation

Study explains how Timothy syndrome mutation causes wiring defects that underlie cognition

Vaccine gives HIV patients a long-term boost

Myasthenia gravis therapies: an interview with Professor Daniel Drachman

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Immunology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Immunology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in